Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.56 |
| ▸ | FNTB | P49356 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778767 | 0.88 | FNTA (0.54) | FNTAFNTBMAPK1POLBALDH1A1 | |
| SCHEMBL5782042 | 0.88 | FNTA (0.54) | FNTAFNTBMAPK1CNR1PGGT1B | |
| SCHEMBL5780727 | 0.87 | FNTA (0.57) | FNTAFNTBPGGT1B | |
| SCHEMBL5777512 | 0.87 | FNTA (0.56) | FNTAFNTBMAPK1KDRPGGT1B | |
| SCHEMBL5783128 | 0.86 | FNTA (0.66) | FNTAFNTBPGGT1B | |
| SCHEMBL5780654 | 0.85 | FNTA (0.54) | FNTAFNTBPGGT1BALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL5780158 | 0.84 | FNTA (0.64) | FNTAFNTBPGGT1B | |
| SCHEMBL5783326 | 0.84 | FNTA (0.58) | FNTAFNTBPGGT1B | |
| SCHEMBL5777043 | 0.83 | FNTA (0.52) | FNTAFNTBPGGT1BALDH1A1LMNA | |
| SCHEMBL5779856 | 0.80 | FNTA (0.54) | FNTAFNTBCNR1PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053105-B2 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-30 | — | — | US | claimed |
| EP-1322635-B1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-22 | — | — | EP | claimed |
| US-20030203904-A1 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-30 | — | — | US | claimed |
| EP-1322635-A1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | claimed |
| WO-2002024682-A1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | claimed |
| US-7053105-B2 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-30 | — | — | US | disclosed |
| EP-1322635-B1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-22 | — | — | EP | disclosed |
| US-20030203904-A1 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-30 | — | — | US | disclosed |
| EP-1322635-A1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024682-A1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203904-A1 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | FNTA, FNTB, RABGGTB | FNTA 1/4885FNTB 2/4885MAPK1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.